About

Dr. Kreda’s laboratory studies mechanisms of delivery of therapeutic molecules in the lung. The main goal is to develop novel and efficient delivery strategies of therapeutic nucleic acids in obstructive lung diseases. The Kreda laboratory is currently involved in designing an efficacious oligonucleotide-based therapeutic approach to correct cystic fibrosis mutations in patients resilient to modulator therapies and orphan mutations that cause primary ciliary dyskinesia (PCD). The laboratory uses state-of-the art technologies and patient-oriented models for precision and personalized medicine approaches.